What is the 13F Pro Quality Score for CRBU?

13F Pro ranks Caribou Biosciences, Inc. (CRBU) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRBU's current score at https://13fpro.ai/research/CRBU (free sign-up required for the full ranking).

Which hedge funds own the most CRBU stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRBU include PFIZER, VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CRBU as soon as new 13F filings post.

Where does 13F Pro source CRBU data?

All Caribou Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Caribou Biosciences, Inc. files with the SEC under CIK 1619856. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRBU in?

Caribou Biosciences, Inc. (CRBU) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRBU research updated on 13F Pro?

CRBU's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Caribou Biosciences, Inc.(CRBU)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1619856 CRBU stock profile & AI dashboard →

13F Pro Quality Score

6.1/100

Rank #2,843 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

1.9/100

Profitability

1.9/100

Balance Sheet

1.2/100

Earnings Quality

30.0/100

Free Cash Flow

1.9/100

Institutional Flow

54.6/100

Revenue Scale

3.4/100

Dilution Risk

2.9/100

CRBU Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Caribou Biosciences, Inc. (CRBU), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRBU at 6.1/100 on a 32-signal composite quality model, placing it at rank #2,843 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.2) and revenue growth (1.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Caribou Biosciences, Inc. reports quarterly revenue of $2.4M, net income of $-25.1M, free cash flow of $-27.1M. Top institutional holders of CRBU by reported 13-F value include PFIZER, VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. CRBU trades on the Nasdaq exchange and files with the SEC under CIK 1619856. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRBU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Caribou Biosciences, Inc. directly from SEC EDGAR. Caribou Biosciences, Inc.'s 13F Pro composite quality score has ranged between 4 and 29 since 2022, currently 6.1 — a declining long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about Caribou Biosciences, Inc.

Quirks, history, and lore behind CRBU — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · small-cap · listed on Nasdaq · headquartered in Berkeley, California.
2
The Numbers
Annual revenue is in the low tens of millions — mostly from licensing and collaborations — while it burns cash developing therapies it hopes will one day dwarf that figure.
3
The History
Founded around 2011 and built on intellectual property spun out of academic research at UC Berkeley, the same institution that gave the world some of the most influential gene-editing science ever published.
4
The Secret
Its core platform uses CRISPR-Cas12a — a lesser-known variant of the famous gene-scissors — which its scientists argue offers precision advantages over the more widely publicized Cas9 cousin.
5
The Lore
The company shares its gene-editing heritage with Jennifer Doudna's orbit — the Nobel-winning UC Berkeley lab that essentially ignited the modern CRISPR revolution — giving it serious scientific street cred from day one.
6
The Giveaway
Its name pairs a large North American deer with the word Biosciences — and its pipeline targets blood cancers and other diseases using its proprietary chRDNA gene-editing technology.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$2.4M

Net Income

Q1 2026

$-25.1M

Free Cash Flow

Q1 2026

$-27.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+11.7% YoY

$11.2MFY 2025

FY19 $5.8MFY20 $12.4MFY24 $10.0MFY25 $11.2M

Net Income

+0.7% YoY

$-148.1MFY 2025

FY19 $-23.4MFY20 $-34.3MFY24 $-149.1MFY25 $-148.1M

Operating Income

+11.0% YoY

$-148.3MFY 2025

FY19 $-34.3MFY20 $-36.1MFY24 $-166.6MFY25 $-148.3M

EPS (Diluted)

+3.6% YoY

$-1.59FY 2025

FY19 —FY20 —FY24 $-1.65FY25 $-1.59

Total Assets

-44.0% YoY

$175.4MFY 2025

FY19 —FY20 $36.0MFY24 $313.3MFY25 $175.4M

Op. Cash Flow

+19.7% YoY

$-111.0MFY 2025

FY19 $-32.0MFY20 $-33.2MFY24 $-138.2MFY25 $-111.0M

Metric	FY 2025	FY 2024	FY 2020	FY 2019	FY 2018
Revenue	$11.2M +11.7%	$10.0M -19.1%	$12.4M +113.6%	$5.8M	—
Net Income	$-148.1M +0.7%	$-149.1M -334.6%	$-34.3M -46.4%	$-23.4M	—
Operating Income	$-148.3M +11.0%	$-166.6M -361.2%	$-36.1M -5.3%	$-34.3M	—
EPS (Diluted)	$-1.59 +3.6%	$-1.65	—	—	—
Total Assets	$175.4M -44.0%	$313.3M +769.2%	$36.0M	—	—
Operating Cash Flow	$-111.0M +19.7%	$-138.2M -316.1%	$-33.2M -3.8%	$-32.0M	—

AI Insight: CRBU Financial Trends

Equity has collapsed from $310M to $102M in seven quarters as cash burn continues, though quarterly losses are narrowing toward $25–26M.

• Equity eroded 67% from $310M in Q2 2024 to $102M in Q1 2026, reflecting sustained net losses with no debt financing.

• Net loss improved from a peak of $-54M in Q2 2025 to $-25M in Q1 2026, a meaningful sequential reduction.

• Operating cash outflow narrowed from $-37M in Q1 2025 to $-21M in Q4 2025, before ticking back to $-27M in Q1 2026.

• Revenue has remained flat, oscillating between $2M and $4M across all eight quarters — no growth trajectory visible.

⚠ At $102M equity and ~$25M quarterly cash burn, the runway appears limited to roughly four quarters without additional financing.

⚠ Operating cash outflow rebounded to $-27M in Q1 2026 after hitting a low of $-21M in Q4 2025 — watch for sustained improvement.

⚠ No debt on the balance sheet means dilutive equity raises are the likely next capital source; monitor share issuance activity.

AI Insight: CRBU Ratio Trends

Caribou Biosciences' capital returns are deteriorating sharply, with ROA worsening from -40.4% in Q2 2024 to -67.3% in Q1 2026.

• ROA has deteriorated steadily from -40.4% in Q2 2024 to -67.3% in Q1 2026, signaling accelerating asset erosion.

• ROE collapsed from -48.6% in Q2 2024 to -98.4% in Q1 2026, nearly doubling the equity destruction rate.

• ROIC worsened from -56.0% in Q2 2024 to -93.2% in Q4 2025, the last quarter with available data.

⚠ TTM ROE hit -130.6% and ROA -89.4% — far worse than any single quarter, suggesting compounding losses over the trailing year.

⚠ OpMargin, NPM, and D/E are entirely absent across all periods, limiting visibility into cost structure and leverage risk.

Get alerted when CRBU's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Caribou Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRBU

PFIZER INC
$8.3M4,690,431 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.2M3,767,228 sh
RENAISSANCE TECHNOLOGIES LLC
$4.9M2,590,497 sh
Kynam Capital Management, LP
$4.8M2,503,302 sh
BlackRock, Inc.
$4.1M2,143,085 sh
TWO SIGMA INVESTMENTS, LP
$3.3M1,759,934 sh
BANK OF AMERICA CORP /DE/
$2.5M1,297,167 sh
abrdn plc
$2.3M1,212,541 sh
MARSHALL WACE, LLP
$2.3M1,205,668 sh
MILLENNIUM MANAGEMENT LLC
$2.0M1,074,421 sh

Fund	Value	Shares
PFIZER INC	$8.3M	4,690,431
VANGUARD CAPITAL MANAGEMENT LLC	$7.2M	3,767,228
RENAISSANCE TECHNOLOGIES LLC	$4.9M	2,590,497
Kynam Capital Management, LP	$4.8M	2,503,302
BlackRock, Inc.	$4.1M	2,143,085
TWO SIGMA INVESTMENTS, LP	$3.3M	1,759,934
BANK OF AMERICA CORP /DE/	$2.5M	1,297,167
abrdn plc	$2.3M	1,212,541
MARSHALL WACE, LLP	$2.3M	1,205,668
MILLENNIUM MANAGEMENT LLC	$2.0M	1,074,421

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRBU on your watchlist

Track score changes the day Caribou Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRBU a good stock to buy?

13F Pro's AI-powered analysis of Caribou Biosciences, Inc. (CRBU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRBU are available on the CRBU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CRBU?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRBU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Caribou Biosciences, Inc.'s investment landscape.